As of 2025-07-12, the EV/EBITDA ratio of Denali Therapeutics Inc (DNLI) is -4.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DNLI's latest enterprise value is 2,058.12 mil USD. DNLI's TTM EBITDA according to its financial statements is -496.00 mil USD. Dividing these 2 quantities gives us the above DNLI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-07-11 | -4.36 |
| 2025-07-10 | -4.39 |
| 2025-07-09 | -4.29 |
| 2025-07-08 | -4.09 |
| 2025-07-07 | -4.07 |
| 2025-07-03 | -4.20 |
| 2025-07-02 | -4.26 |
| 2025-07-01 | -3.98 |
| 2025-06-30 | -3.99 |
| 2025-06-27 | -4.03 |
| 2025-06-26 | -4.14 |
| 2025-06-25 | -4.13 |
| 2025-06-24 | -4.11 |
| 2025-06-23 | -3.89 |
| 2025-06-20 | -3.96 |
| 2025-06-18 | -4.02 |
| 2025-06-17 | -4.00 |
| 2025-06-16 | -4.18 |
| 2025-06-13 | -4.16 |
| 2025-06-12 | -4.27 |
| 2025-06-11 | -4.35 |
| 2025-06-10 | -4.37 |
| 2025-06-09 | -4.19 |
| 2025-06-06 | -4.20 |
| 2025-06-05 | -4.06 |
| 2025-06-04 | -4.12 |
| 2025-06-03 | -3.98 |
| 2025-06-02 | -3.99 |
| 2025-05-30 | -3.77 |
| 2025-05-29 | -3.86 |
| 2025-05-28 | -3.72 |
| 2025-05-27 | -3.77 |
| 2025-05-23 | -3.83 |
| 2025-05-22 | -3.90 |
| 2025-05-21 | -3.91 |
| 2025-05-20 | -4.08 |
| 2025-05-19 | -3.97 |
| 2025-05-16 | -3.93 |
| 2025-05-15 | -4.04 |
| 2025-05-14 | -3.99 |
| 2025-05-13 | -4.07 |
| 2025-05-12 | -4.23 |
| 2025-05-09 | -4.11 |
| 2025-05-08 | -4.12 |
| 2025-05-07 | -4.09 |
| 2025-05-06 | -3.99 |
| 2025-05-05 | -4.58 |
| 2025-05-02 | -4.71 |
| 2025-05-01 | -4.60 |
| 2025-04-30 | -4.77 |